Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight With Co-morbidity (ASCEND)

NCT06862791 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06862791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06862791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight With Co-morbidity (ASCEND)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
February 18, 2025
Completion date
May 11, 2026
Enrollment
377 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

obesity or overweight